This prospective, randomized, single-blind, controlled clinical investigation evaluates the efficacy and safety of ZKAREĀ®, a topical polymeric gel dressing, and its accessory applicator ZKAPIĀ®, for the treatment of chronic, hard-to-heal ulcers. The study includes 134 ulcers of different etiologies-pressure ulcers, neuropathic diabetic foot ulcers, and venous leg ulcers-meeting predefined selection criteria. Participants are randomized to receive either ZKAREĀ® in addition to standard wound care or standard care alone. The primary efficacy endpoint is the change in wound condition assessed through the RESVECH 2.0 scale, recorded at baseline and throughout treatment and follow-up visits. The primary safety endpoint is the incidence of serious adverse events (SAEs). Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, quality-of-life measures (DLQI), patient satisfaction, investigator global assessment, cost-effectiveness, and product usability. The study aims to generate evidence on the performance, safety, and clinical usefulness of ZKAREĀ® for chronic wound management.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
RESVECH Scale 2.0
Timeframe: 12 weeks or wound healing
Incidence of Serious Adverse Events (SAEs)
Timeframe: 12 weeks